Literature DB >> 20650775

[Effects of sophoridine on the growth and expressions of p53 and vascular endothelial growth factor of transplanted solid tumor SW480 in nude mice].

Qi-rui Wang1, Chun-hua Li, Xiu-qiong Fu, Ya-wei Liu, Jing Tang, Qin Fan, Xue-gang Sun.   

Abstract

OBJECTIVE: To study the effects of sophoridine on the transplanted solid tumor SW480 and the expression of p53 and vascular endothelial growth factor (VEGF) in the tumor in nude mice.
METHODS: The nude mouse model bearing transplanted solid tumor SW480 was established, and the changes in the volume and weight of the tumor were determined after treatment of the mice with sophoridine. Western blotting and immunohistochemistry were employed to examine the expressions of p53 and VEGF proteins, respectively, and fluorescence quantitative PCR used to detect their mRNA expressions in the tumor tissue.
RESULTS: The volume and weight of the tumor xenograft in sophoridine group decreased in comparison with those in the control group. Sophoridine treatment resulted in lowered expressions of p53 and VEGF at both the protein and mRNA levels in the tumor explants as compared with the control group, with a tumor inhibition rate of 34.07% in nude mice.
CONCLUSION: Sophoridine can inhibit the growth of transplanted solid tumor of human SW480 cell line, the mechanism of which involves the inhibition of p53 and VEGF expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20650775

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  2 in total

1.  Meta-Analysis of Oxaliplatin-Based Chemotherapy Combined With Traditional Medicines for Colorectal Cancer: Contributions of Specific Plants to Tumor Response.

Authors:  Menghua Chen; Brian H May; Iris W Zhou; Charlie C L Xue; Anthony L Zhang
Journal:  Integr Cancer Ther       Date:  2015-08-06       Impact factor: 3.279

2.  Synthesis and biological evaluation of 12-N-p-chlorobenzyl sophoridinol derivatives as a novel family of anticancer agents.

Authors:  Chongwen Bi; Cheng Ye; Yinghong Li; Wuli Zhao; Rongguang Shao; Danqing Song
Journal:  Acta Pharm Sin B       Date:  2016-04-14       Impact factor: 11.413

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.